President Clinton Unveils National AIDS Policy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

WASHINGTON--President Clin-ton calls his new national AIDS strategy an important milestone in the history of efforts to end the pandemic that has killed more than 343,000 Americans since 1981. "In the 15 years of this epidemic, we have never had such a unified strategy," the President said. "These goals will guide our work in the coming term and, more specifically, in the coming year."

WASHINGTON--President Clin-ton calls his new national AIDS strategyan important milestone in the history of efforts to end the pandemic thathas killed more than 343,000 Americans since 1981. "In the 15 yearsof this epidemic, we have never had such a unified strategy," thePresident said. "These goals will guide our work in the coming termand, more specifically, in the coming year."

Six General Goals of the National AIDS Strategy

The new policy was drafted by the White House's Office of National AIDSPolicy after consultation with a number of federal agencies, health andmedical groups, religious organizations, and AIDS advocates.

"The development of a national AIDS strategy is a historic undertaking,"said Patricia S. Fleming, director of the AIDS office. She emphasized thebreadth of the new policy, which involves all federal departments and agenciesengaged in HIV-related work; reaches out to communities and the privatesector; and identifies areas where the federal government should focusits efforts.

"The national AIDS strategy provides a foundation for the continuingpublic-private partnerships that are essential to our success in endingthis epidemic," Ms. Fleming added.

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content